Carbylan Therapeutics (CBYL) Misses Q2 EPS by 16c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Carbylan Therapeutics Announces Second Quarter 2015 Financial Results
August 11, 2015 4:01 PM EDTPALO ALTO, Calif., Aug. 11, 2015 (GLOBE NEWSWIRE) -- Carbylan® Therapeutics (NASDAQ: CBYL), a specialty pharmaceutical company focused on the development of novel and proprietary combination therapies, today announced financial results for the second quarter ended June 30, 2015.
David Renzi, President and CEO of Carbylan Therapeutics commented, "During the quarter, we continued to progress with our phase 3 clinical program for Hydros-TA in the treatment of osteoarthritis pain of the knee. Most importantly, we completed the enrollment of our 510 subject COR1.1 trial, which is the first of the two pivotal clinical trials... More
